Overview
- Moderna and Merck said their individualized mRNA vaccine, intismeran autogene, reduced recurrence in a pivotal trial of resected melanoma when given with Merck’s Keytruda.
- The vaccine is custom made for each patient by sequencing the tumor, selecting dozens of neoantigen targets and producing a bespoke mRNA shot to train the immune system.
- The companies are preparing full trial data for a scientific meeting and plan regulatory engagement with the U.S. Food and Drug Administration as a possible next step.
- Markets have rapidly repriced Moderna and the company has signaled near‑term financing needs, although headline sales forecasts and analyst price targets vary widely.
- Key open questions include detailed hazard ratios and absolute benefit, overall survival and safety tables, and whether bespoke manufacturing can scale affordably to other cancers.